We are live on ! Find out more
FLAM

First Light Asset Management Portfolio holdings

AUM $1.12B
1-Year Est. Return 114.45%
This Fund
S&P 500
This Quarter Est. Return
+7.12%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$146M
AUM Growth
-$2.25M
Cap. Flow
-$1.85M
Cap. Flow %
-1.27%
Top 10 Hldgs %
49.44%
Holding
70
New
2
Increased
36
Reduced
2
Closed
8

Sector Composition

Rank Sector Weight
1 Healthcare 88.7%
2 Consumer Staples 1.01%
3 Financials 0.29%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NEO icon
1
NeoGenomics
NEO
$1.96B
$13M 8.88%
2,490,848
+453,320
+22% +$2.33M
TLGT
2
DELISTED
Teligent, Inc
TLGT
$11.4M 7.81%
122,450
+3,018
+3% +$193K
SPNC
3
DELISTED
Spectranetics Corp
SPNC
$7.76M 5.31%
292,124
+7,146
+3% +$192K
AKRX
4
DELISTED
Akorn Inc
AKRX
$7.74M 5.3%
213,512
+5,209
+3% +$187K
ATRC icon
5
AtriCure
ATRC
$1.92B
$7.31M 5%
496,671
+12,351
+3% +$197K
SRGA
6
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$6.4M 4.38%
44,643
+1,104
+3% +$160K
ENZ
7
DELISTED
Enzo Biochem, Inc.
ENZ
$5.85M 4%
1,136,575
+26,959
+2% +$144K
NXTM
8
DELISTED
NxStage Medical Inc.
NXTM
$4.54M 3.11%
346,177
+160,097
+86% +$2.16M
HBIO icon
9
Harvard Bioscience
HBIO
$27.5M
$4.35M 2.98%
106,384
+4,955
+5% +$228K
STRM
10
DELISTED
Streamline Health Solutions
STRM
$3.92M 2.68%
56,414
+1,309
+2% +$91.8K
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$3.78M 2.59%
1,059,270
+27,150
+3% +$107K
LGND icon
12
Ligand Pharmaceuticals
LGND
$5.76B
$3.59M 2.45%
122,415
+3,211
+3% +$107K
QDEL icon
13
QuidelOrtho
QDEL
$1.14B
$3.57M 2.44%
132,885
+3,341
+3% +$79.7K
TECH icon
14
Bio-Techne
TECH
$11.2B
$3.42M 2.34%
146,264
+3,552
+2% +$83.3K
SPPI
15
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$3.08M 2.11%
378,537
+10,647
+3% +$83.3K
TEAR
16
DELISTED
TearLab Corporation
TEAR
$3.05M 2.09%
89,646
+2,233
+3% +$94.5K
OMCL icon
17
Omnicell
OMCL
$1.61B
$3.04M 2.08%
111,191
-40,071
-26% -$1.1M
STAA icon
18
STAAR Surgical
STAA
$1.21B
$3.03M 2.07%
284,730
+80,113
+39% +$952K
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.9M 1.98%
189,766
+4,382
+2% +$67.1K
ALKS icon
20
Alkermes
ALKS
$8.22B
$2.81M 1.92%
65,423
+1,739
+3% +$78K
SNY icon
21
Sanofi
SNY
$103B
$2.8M 1.92%
49,633
+43,953
+774% +$2.36M
NVDQ
22
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.64M 1.81%
208,121
+4,814
+2% +$70.1K
ELGX
23
DELISTED
Endologix Inc
ELGX
$2.46M 1.68%
23,160
+13,875
+149% +$1.93M
SGNT
24
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$2.19M 1.5%
70,542
+1,888
+3% +$51.1K
LCI
25
DELISTED
Lannett Company, Inc.
LCI
$1.95M 1.33%
10,664
-10,209
-49% -$1.63M

Similar funds

First Light Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, First Light Asset Management held 70 positions worth $146M, down 1.5% from $148M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

First Light Asset Management's Q3 2014 filing shows 2 new, 36 increased, 2 reduced and 8 closed positions. Its largest new stake was Ionis Pharmaceuticals: 27,290 shares worth $1.06M. The largest sale was VOCERA COMMUNICATIONS, INC., an estimated $3.56M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier, followed by Consumer Staples and Financials.

  • First Light Asset Management's largest Q3 2014 buy was Ionis Pharmaceuticals: 27,290 shares worth $1.06M.
  • First Light Asset Management added most to Sanofi in Q3 2014, an estimated $2.36M increase.
  • First Light Asset Management's biggest Q3 2014 reduction was Lannett Company, Inc., cutting an estimated $1.63M.
  • First Light Asset Management fully exited VOCERA COMMUNICATIONS, INC. in Q3 2014, selling an estimated $3.56M.
  • First Light Asset Management's ten largest holdings make up 49% of its $146M portfolio in Q3 2014.
  • First Light Asset Management opened 2 new positions and closed 8 in Q3 2014.
  • First Light Asset Management's portfolio value fell 1.5% quarter-over-quarter to $146M.

Based on First Light Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.